The Triple Revolution: How Centanafadine is Redefining ADHD Treatment
The landscape of Attention Deficit Hyperactivity Disorder (ADHD) treatment is on the verge of a historic transformation. For decades, patients have had to choose between stimulants (like Adderall or Ritalin) and traditional non-stimulants (like Strattera). But a third way is coming: Centanafadine.
At Mark Agresti MD LLC, we pride ourselves on bringing the future of psychiatry to our West Palm Beach community. Dr. Agresti and our team are closely monitoring this breakthrough to ensure our patients at drmarkagresti.com are the first to benefit from the next generation of “Triple Reuptake” science.
The Mechanism: The Power of Three
Most ADHD medications target one or two neurotransmitters. Centanafadine is a Norepinephrine, Dopamine, and Serotonin Reuptake Inhibitor (NDSRI). This “Triple Reuptake” mechanism is what makes the drug revolutionary. 
• Dopamine & Norepinephrine: Like traditional stimulants, Centanafadine helps with focus, drive, and the “executive function” of the brain. 
• The Serotonin Edge: Unlike standard stimulants, Centanafadine also modulates serotonin. This addition is a game-changer for managing the emotional dysregulation, impulsivity, and anxiety that often accompany ADHD but are frequently ignored by older drugs. 
• Inward-Facing Capture: Recent 2026 structural data shows that Centanafadine captures the dopamine transporter in an “inward-facing” conformation, a unique molecular signature that may explain its robust efficacy and clean safety profile. 
Why It’s a Revolution in Patient Care
Centanafadine is being described as a “stimulant with non-stimulant characteristics.” It offers the rapid onset usually only seen in stimulants (with clinical benefits appearing as early as Week 1) but with the lower abuse potential and smoother side-effect profile of a non-stimulant. 
• Muscle & Motor Safety: It avoids the “jitteriness” and motor tics sometimes associated with high-dose stimulants.
• Sleep & Appetite: Clinical trials in late 2025 and early 2026 demonstrated that Centanafadine has a much more favorable impact on sleep and appetite than traditional amphetamines.
Availability: When Can You Get It?
As of March 2026, Centanafadine is an investigational compound under FDA Priority Review. 
• United States: The FDA has set a “PDUFA” target action date for July 24, 2026. If approved, we expect the drug to be available at pharmacies in late 2026 or early 2027. 
• Global Status: Currently, Centanafadine is not available for commercial prescription anywhere in the world. It is exclusively being administered within Phase 3 clinical trials across the US, Europe, and Japan. The US is currently on the fastest track for public release. 
Modern ADHD Care with Mark Agresti, MD
At Mark Agresti MD LLC, we don’t just treat symptoms; we treat people. The addition of an NDSRI like Centanafadine to the pharmacopeia allows us to tailor treatment specifically to patients who struggle with the “emotional” side of ADHD or those who cannot tolerate the side effects of standard stimulants. 
Is your current ADHD treatment falling short? Stay ahead of the curve. Visit drmarkagresti.com to learn more about our innovative approach to mental health and to stay updated on the release of Centanafadine.